Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab

References

• Nestle FO, Kaplan DH, Barker J. Psoriasis. New Engl J Med 2009;361:496–509.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207–1211.
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Gisondi P. Psoriasis and metabolic comorbidities: the importance of well-designed prospective studies. Dermatology 2008;217:222–224.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009;35:313–324.
   PubMed Web of Science ®Google Scholar
• Rashmi R, Rao SJ, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009;34:658–663.
   PubMed Web of Science ®Google Scholar
• Yildirim M, Inaloz HS, Baysa V, Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003;17:34–36.
   PubMed Web of Science ®Google Scholar
• Rocha-Pereira P, Santos-Silva A, Rebelo I, Figneiredo A, Quintanilha A, Teixeira F. Erythrocyte damage in mild and severe psoriasis. Br J Dermatol 2004;150:232–244.
   PubMed Web of Science ®Google Scholar
• Seifert O, Holmberg J, Linnarsson BM. Decreased activity of neutrophil glutathione peroxidase in chronic plaque psoriasis. J Am Acad Dermatol 2007;57:528–529.
   PubMed Web of Science ®Google Scholar
• Baz K, Cimen MY, Kokturk A, Yazici AC, Eskandari G, Ikizoglu G, Api H, Atik U. Oxidant/antioxidant status in patients with psoriasis. Yonsei Med J 2003;44:987–990.
   PubMed Web of Science ®Google Scholar
• Okayama Y. Oxidative stress in allergic and inflammatory skin diseases. Current Drug Targets-Inflamm Allergy 2005;4: 517–519.
   PubMedGoogle Scholar
• Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 2009;47: 891–905.
   PubMed Web of Science ®Google Scholar
• Korkina L, Trakhtman P, De Luca C, Leoni L, Raskovic D, Pastore S. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks? Drugs Today 2010;46:119–136.
   PubMed Web of Science ®Google Scholar
• Altomare G, Arcangeli F, Berardesca E, Calzavara Pinton P, Giannetti A, Girolomoni G, Lotti T, Martini P, Peserico A, Simonacci M, Vena GA. Biological drugs: differing mechanisms of action. G Ital Dermatol Venerol 2009;144:1–18.
   PubMedGoogle Scholar
• Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, Efalizumab and immunosuppression. Arch Dermatol 2009;145:937–942.
   PubMed Web of Science ®Google Scholar
• Evans R, Patzak I, Svensson L, De Filippo K, Jones K, McDowall A, Hogg N. Integrins in immunity. J Cell Sci 2009;122:215–225.
   PubMed Web of Science ®Google Scholar
• Van Noesel C, Miedema F, Brouwer M, De Rie MA, Aarden LA, Van Lier RAW. Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature 1988;333: 850–852.
   PubMed Web of Science ®Google Scholar
• Jullien D, Prinz JC, Langley RGB, Caro I, Dummer W, Joshi A, Dedrick K, Natta P. T-cell modulation for the treatment of chronic plaque psoriasis with Efalizumab (Raptiva™): mechanisms of action. Dermatology 2004;208:297–306.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–2013.
   PubMed Web of Science ®Google Scholar
• Schmits R, Kundig TM, Baker DM, Shumaker G, Simard JJ, Duncan G, Wakeham A, Shahinian A, van der Heiden A, Bachmann MF, Ohashi PS, Mak TW, Hickstein DD. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumors. J Exp Med 1996;183: 1415–1426.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JYM, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Pastore S, Gubinelli E, Leoni L, Raskovic D, Korkina L. Biological drugs targeting the immune response in the therapy of psoriasis. Biologics 2008;2:687–697.
   PubMedGoogle Scholar
• Frampton JE, Plosker GL. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol 2009;10:51–72.
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272–284.
   PubMed Web of Science ®Google Scholar
• Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA-1) monoclonal antibody and re-engineering of the humanized antibody for binding to Rhesus LFA-1. J Immunol 1996;157:4986–4995.
   PubMed Web of Science ®Google Scholar
• Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol 2008;47:1019–1023.
   PubMed Web of Science ®Google Scholar
• Brown GE, Silver GM, Reiff J, Allen RC, Fink MP. Polymorphonuclear neutrophil chemiluminescence in whole blood from blunt trauma patients with multiple injuries. J Trauma 1999;46:297–305.
   PubMedGoogle Scholar
• Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med Metab B 1976;15:212–216.
   Google Scholar
• Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1984;249:7130–1739.
   Google Scholar
• Aebi H. Catalase in vitro. Methods Enzymol 1974;105: 121–126.
   Google Scholar
• Paglia DE, Valentine WN. Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158–169.
   PubMed Web of Science ®Google Scholar
• Valacchi G, Van der Vliet A, Schock BC, Okamoto T, Obermuller-Jevic U, Cross CE, Packer L. Ozone exposure activates oxidative stress responses in murine skin. Toxicology 2002;179:163–170.
   PubMed Web of Science ®Google Scholar
• De Luca C, Filosa A, Grandinetti M, Maggio F, Lamba M, Passi S. Blood antioxidant status and urinary levels of catecholamine metabolites in β-thalassemia. Free Radic Res 1999;30:453–462.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 2003;217:663–669.
   Google Scholar
• Deeva I, Mariani S, De Luca C, Pacifico V, Leoni L, Raskovic D, Kharaeva Z, Korkina L, Pastore S. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine 2010;49:63–170.
   Web of Science ®Google Scholar
• Schön MP. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy and safety. Clinics Dermatol 2008;26:509–514.
   PubMed Web of Science ®Google Scholar
• Kandula S, Abraham C. LFA-1 on CD4+ T cells is required for optimal antigen-dependent activation in vivo. J Immunol 2004;173:4443–4451.
   PubMed Web of Science ®Google Scholar
• Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009;38:372–381.
   PubMed Web of Science ®Google Scholar
• Bruch-Gerharz D, Fehsel K, Suschek C, Michel G, Ruzicka T, Kolb-Bachofen V. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996;184:2007–2012.
   PubMed Web of Science ®Google Scholar
• Bruch-Gerharz D, Ruzicka T, Kolb-Bachofen V. Nitric oxide and its implications in skin homeostasis and disease – a review. Arch Dermatol Res 1998;290:643–651.
   PubMed Web of Science ®Google Scholar
• Kharaeva Z, Gostova E, De Luca C, Raskovic D, Korkina L. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009;25:295–302.
   PubMed Web of Science ®Google Scholar
• Korkina L, Pastore S. The role of redox regulation in the normal physiology and inflammatory diseases of the skin. Front Biosci 2009;1:123–141.
   Google Scholar
• Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010;12: 1009–1059.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993;57: 715S–724S.
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349–361.
   PubMed Web of Science ®Google Scholar
• Flohe L, Ursini F. Peroxidase: a term of many meanings. Antioxid Redox Signal 2008;10:1485–1490.
   PubMed Web of Science ®Google Scholar
• Alin P, Danielson UH, Mannervik B. 4-hydroxyalk-2-enals are substrates for glutathione transferase. FEBS Lett 1985;179: 267–279.
   PubMed Web of Science ®Google Scholar
• Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, Osawa TA. Activation of stress signaling pathways by the end product of lipid peroxidation. J Biol Chem 1999;274:2234–2242.
   PubMed Web of Science ®Google Scholar
• Zhang H, Forman HJ. Signaling pathways involved in phase II gene induction by alpha, beta-unsaturated aldehydes. Toxicol Ind Health 2009;25:269–278.
   PubMed Web of Science ®Google Scholar
• Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006;15:549–556.
   Web of Science ®Google Scholar